UK: RISE IN TB CASES CAUSES CONCERN

Article Abstract:

There is growing concern about the increase in the number of tuberculosis (TB) cases diagnosed in the UK. Research has revealed that there were almost 7,000 cases of TB in Britain in 1999, an 80% rise over 10 years. In theory anyone can catch TB, which is spread through droplets in the air, but it is largely concentrated amongst immigrant communities and the poor. The problem is that failure to take drugs can lead to the disease developing resistance. Multi drug-resistant (MDR) TB spreads rapidly and requires the patient to undergo long-term treatment. The charity TB alert argues that not enough is being done to avert a "human disaster". Professor John Grange, at the Centre for Infectious Diseases at University College London, wants to see the number of specialist TB nurses increased in hotspots to a ratio of at least one for every 50 cases.

Market information - general, Research and Testing Services

---

UK: AVANDIA TO HELP DIABETES CASES

Article Abstract:

A new drug called Avandia, has been launched with the aim of helping people in the UK with diabetes. Avandia will be used to treat type 2 diabetes, and scientists are hopeful that it could also be used to help patients with heart conditions. It works by reducing blood glucose levels in a similar way to insulin. Type 2 diabetes is a disease that affects mostly middle-aged people who are overweight. It accounts for 90% of all diabetes cases, and is estimated to affect 2mn people in the UK. It is predicted that Avandia will add an additional GB[pound] 150mn of costs on to the NHS, with health authorities predicting first year costs of GB[pound] 5mn.

Pharmaceutical preparations, Ethical Preparations, Drugs

---

UK: PROFILE THERAPEUTICS' NEW AAD SYSTEM

Article Abstract:

Profile Therapeutics' new Adaptive Aerosol Delivery (AAD) system is described as a way of treating respiratory diseases such as asthma. The UK-based firm's drug-delivery system enables usage and dosage information to be retrieved online and provides the potential to deliver a broad array of treatments through the lungs. Profile Therapeutics noted that the respiratory disease market is expanding at about 12% annually and is valued at US$ 12bn. However, in terms of the wider range of treatments open to the AAD system, the market is far larger.

Product information, Drug Delivery Systems, Product introduction, Profile Therapeutics

Similar abstracts:

• Abstracts: UK: DECLINE IN FARMING INCOMES IN 1999. UK: NEW MAFF POLICY UNIT TO BE SET UP? UK: FARMING PRACTICES AFFECT THRUSH POPULATION
• Abstracts: UK: OUTWARD INVESTMENT LEVELS SURPASS US. UK: MANUFACTURING FIRMS CUT INVESTMENT. UK: PUPIL-TEACHER RATIO STILL NOT GOOD
• Abstracts: UK: FASHION FOR OBSCURE INTERNET SITE NAMES. Nostalgia revisited. UK: FAVOURABLE RESULTS FOR MEMORY
• Abstracts: Chain store sector set for mergers UK: NEW CONCEPT STORE IN KENSINGTON FOR M&S

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.